|
1 Indications And Usage Harvoni Is Indicated For The Treatment Of Adults And Pediatric Patients 3 Years Of Age And Older With Chronic Hepatitis C Virus (Hcv) [See Dosage And Administration (2.2 And 2.3) And Clinical Studies (14) ] : Genotype 1, 4, 5, Or 6 Infection Without Cirrhosis Or With Compensated Cirrhosis Genotype 1 Infection With Decompensated Cirrhosis, For Use In Combination With Ribavirin Genotype 1 Or 4 Infection Who Are Liver Transplant Recipients Without Cirrhosis Or With Compensated Cirrhosis, For Use In Combination With Ribavirin Harvoni Is A Fixed-Dose Combination Of Ledipasvir, A Hepatitis C Virus (Hcv) Ns5a Inhibitor, And Sofosbuvir, An Hcv Nucleotide Analog Ns5b Polymerase Inhibitor, And Is Indicated For The Treatment Of Chronic Hepatitis C Virus (Hcv) In Adults And Pediatric Patients 3 Years Of Age And Older: Genotype 1, 4, 5, Or 6 Infection Without Cirrhosis Or With Compensated Cirrhosis Genotype 1 Infection With Decompensated Cirrhosis, In Combination With Ribavirin Genotype 1 Or 4 Infection Who Are Liver Transplant Recipients Without Cirrhosis Or With Compensated Cirrhosis, In Combination With Ribavirin. ( 1 )
|